NDAORALSOLUTION
Approved
May 2015
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYCOFENIX is a fixed-dose oral solution combining guaifenesin (expectorant), hydrocodone bitartrate (opioid antitussive), and pseudoephedrine HCl (decongestant) approved in 2015. It is indicated for symptomatic relief of cough and congestion associated with upper respiratory conditions. The combination mechanism targets multiple pathways: mucus clearance, cough suppression via central opioid action, and nasal decongestion via sympathomimetic activity.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30), suggesting stable commercial operations but limited team expansion opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HYCOFENIX currently shows zero linked job postings, indicating minimal hiring activity and limited near-term career movement on this brand. Working on this product offers experience in mature market management and opioid-containing combination therapeutics but does not signal growth-phase opportunity.
Brand ManagerField Sales Representative
Worked on HYCOFENIX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.